Skip to main content

Spinal Cord Injury

Spinal cord injury (SCI) is the archetypal reconstructive neuro-urology population. NLUTD is common after SCI above the conus; before the mid-1970s, renal failure and other urinary tract complications were a leading cause of death in people with SCI.[3][25] The level of injury, completeness, and interval since injury all drive the NLUTD phenotype.[1][2][3]

For general NLUTD principles see Neurogenic Lower Urinary Tract Dysfunction; for a life-threatening SCI-specific emergency see Autonomic Dysreflexia. For the reconstructive procedures referenced throughout, see Intradetrusor OnabotulinumtoxinA, Bladder Augmentation, Catheterizable Channels, and the Ileal Conduit salvage pathway.

Epidemiology​

  • US prevalence about 250,000–300,000; incidence about 17,000/year.
  • Leading etiologies: motor-vehicle trauma, falls, violence, sports, non-traumatic (transverse myelitis, tumor, ischemia).
  • Average age at injury is rising (currently about 43 years); aging of the SCI population brings coexisting BPH, prostate cancer, and obesity into reconstructive planning.
  • Life expectancy after traumatic SCI remains shorter than in the general population, with higher or complete injuries associated with poorer survival. Urologic complications and pressure injuries still warrant prevention and longitudinal care.[25][1]

Pathophysiology by Level​

Injury levelPhase after injuryDominant urodynamic phenotype
Any levelAcute / spinal-shock (days–~6 weeks, range up to months)Retention is typical; in a prospective cohort of 54 patients studied within 40 days of SCI, 20/54 (37%) had an acontractile detrusor and 34/54 (63%) had unfavorable urodynamic findings, including DO, DSD or high storage pressure.[7]
Above T6 (high cervical / upper thoracic)After spinal shockDetrusor overactivity + DSD + risk of autonomic dysreflexia
T6–T12 / suprasacralAfter spinal shockDO + DSD; lower AD risk
Conus (T12–L1 region)Stable from onsetVariable — can resemble suprasacral DSD or sacral areflexia
Cauda equina / sacral / infrasacralStable from onsetDetrusor areflexia + denervated EUS; retention, overflow, stress incontinence

In a urodynamic series of traumatic SCI, 81.5% of suprasacral injuries showed detrusor hyperreflexia with or without DSD, 9.2% areflexia and 9.2% normal bladders; of five sacral injuries, four had areflexia.[8] In this 70-patient traumatic SCI series, low compliance occurred in 41/65 suprasacral and 1/5 sacral injuries, whereas detrusor leak-point pressure >40 cmH2O occurred in 47/65 and 5/5, respectively; neurologic level predicted the urodynamic pattern imperfectly.[8]

Spinal shock and early bladder management​

  • Place an indwelling catheter for the acute phase to keep the bladder decompressed and monitor fluids; do not leave it in place by default once the patient is stable.
  • Transition to CIC as soon as fluid intake is controlled and the patient is stable. In a retrospective acute-care protocol of 101 patients with traumatic SCI, voluntary anal contraction triggered a trial of void; three consecutive post-void residuals ≤200 mL without incontinence then defined functional bladder.[11]
  • Because unsafe storage pressures can appear during the "areflexic" phase, EAU 2026 advises first urodynamics as soon as possible after critical care and within three months of SCI, without waiting for spinal shock to end.[5][7]

Initial Evaluation and Surveillance Cadence​

Per AUA/SUFU 2021 risk-stratified framework.[1][2] SCI generally requires assessment as unknown-risk, followed by classification using renal function, imaging, and urodynamics. Reassess when neurological function stabilizes, with earlier investigation for concerning changes. See the NLUTD risk and surveillance framework.

Baseline workup (timed to clinical stability and risk):

  • History and exam (including AD triggers, skin, bowel program)
  • Urinalysis, serum Cr / eGFR
  • Renal ultrasound
  • Video-urodynamics. Documents DO, DSD, DLPP, compliance, VUR
  • PVR and bladder diary

Longitudinal surveillance (high-risk):

  • Annual clinical review; obtain urine testing for symptoms rather than routine infection screening
  • Renal ultrasound annually for high-risk disease; the 1–2-year interval belongs to stable moderate-risk disease
  • Assess renal function annually; in SCI with reduced muscle mass, creatinine-based eGFR can overestimate measured GFR, so consider cystatin C-based eGFR when available.[1][26]
  • Repeat urodynamics after treating storage or voiding parameters that threaten the upper tracts .[2] For high-risk SCI, schedule further testing according to risk and treatment plan , with earlier investigation for new symptoms, hydronephrosis, declining renal function or AD.[2][5]
  • Cystoscopy for an indication such as hematuria, recurrent UTI, or suspected structural pathology; not annual screening solely because a catheter is present

AUA/SUFU (statements 13–15) sets the intervals: low-risk stable patients need no surveillance imaging or urodynamics; moderate-risk patients need annual history/exam and renal function with upper-tract imaging every 1–2 years; high-risk patients need annual history, exam, renal function and upper-tract imaging, with urodynamics repeated when clinically indicated. EAU 2026 is more intensive, suggesting ultrasound about every six months in high-risk patients and a urodynamic baseline repeated during follow-up.[1][5]

Long-term outcome data support continuing this surveillance for life rather than treating a stable patient as low risk indefinitely. In a retrospective cohort of 43 SCI patients followed for a median of 45 years (range 40–50), recurrent UTI occurred in all patients, and vesicoureteral reflux (33%), bladder stones (49%), and hydronephrosis (47%) continued to appear throughout follow-up; most complications first occurred in the first 25 years after injury, but new complications still arose later, and male sex, cervical injury, and condom-catheter use tracked with a higher complication burden.[17]

Management​

Emptying strategies[2][3][4]​

Select according to storage safety, hand function, caregiver support, anatomy, and patient goals; when catheter drainage is indicated, AUA/SUFU 2021 recommends CIC over indwelling catheters and suprapubic over urethral drainage for appropriately selected patients requiring a chronic catheter (both Strong Recommendations, Grade C).[2]

  1. Clean intermittent catheterization (CIC). AUA/SUFU recommends it over indwelling catheters for bladder emptying .[2] Typical practice is 4–6×/day; hydrophilic catheters are associated with fewer UTIs, and bladder volumes should stay below about 400–500 mL.[5] Among SCI registry respondents now using an indwelling catheter or urinary conduit who had stopped CIC, about 42% reported stopping within 12 months of starting it; review dexterity, leakage and infection burden early.[5] In a retrospective cohort of 308 SCI patients evaluated a mean 18.7 years after injury, upper-tract abnormalities occurred in 56 chronic Foley users (18.2% of the entire cohort), 20 CIC users (6.5%), and 24 spontaneous voiders (7.8%).[14] Foley use independently predicted low creatinine clearance and was associated with proteinuria, whereas vesicoureteral reflux independently predicted upper-tract imaging abnormalities.[14] A Canadian cost-effectiveness model likewise found CIC the dominant strategy (more QALYs at lower cost) versus suprapubic or indwelling urethral catheters from a public-payer perspective.[14][15]
  2. Indwelling SPC. When dexterity or caregiver support or body habitus preclude CIC. AUA/SUFU recommends it over an indwelling urethral catheter in appropriately selected patients who need a chronic indwelling catheter .[2]
  3. Indwelling urethral catheter. Last-line; high urethral-erosion risk in men, bladder-neck and sphincter damage in women.
  4. Reflex voiding with external condom drainage (men). Historically common; requires confirmed safe detrusor pressures and low outlet resistance, often achieved by sphincterotomy or botulinum toxin for DSD. Triggering can provoke autonomic dysreflexia at or above T6. Not practical in women, who have no condom-drainage equivalent.[5]
  5. Credé or Valsalva. Discourage because they raise intravesical pressure during attempted emptying and may provoke sphincter contraction; use only when urodynamics show safe voiding pressure and effective emptying.[5]

In the US National Spinal Cord Injury Database (24,762 patients at discharge from rehabilitation, 1972 to 2005), CIC at discharge rose from 12.6% in 1972 to a peak of 56.2% in 1991.[23] Among 12,984 patients with follow-up data, only 20% of those discharged on CIC remained on it, whereas 71.1% of those discharged with an indwelling catheter still used one at 30 years.[23] In a 1,479-person observational cohort from the United States and Canada, 51% used CIC, 18% an indwelling catheter, 18% voiding and 13% had had bladder surgery.[24] Compared with CIC, an indwelling catheter or prior surgery was associated with better patient-reported bladder function and voiding with worse function, in both paraplegia and tetraplegia; the design shows associations only, and people with worse bladder problems may have been more likely to enroll.[24]

Pharmacologic​

  • Antimuscarinics are first-line for neurogenic detrusor overactivity.[5] AUA/SUFU 2021 conditionally permits a β3 agonist alone or with an antimuscarinic for NLUTD storage parameters (Grade C), and combination therapy is an option when monotherapy inadequately controls symptoms.[2] EAU 2026 strongly advises against using β3 agonists to reduce urodynamically proven NDO.[2][5] See Neurogenic Lower Urinary Tract Dysfunction for the agent table.
  • Intradetrusor onabotulinumtoxinA 200 U (the labeled neurogenic dose) is effective for neurogenic DO in SCI; in a mixed MS/SCI trial, the median time to patient-requested re-treatment after 200 U was 256 days.[6] Patients who void spontaneously must be counseled about retention and the possible need for CIC before treatment .[6][2] AUA/SUFU found no efficacy difference between 200 U and 300 U, with a dose-dependent rise in retention and CIC. In the phase 3 trial (MS and SCI), patients not catheterizing at baseline started CIC for retention in 35% at 200 U and 42% at 300 U versus 10% with placebo, and 300 U added no efficacy or duration benefit.[4][6]
  • α-blockers may improve voiding parameters in selected spontaneous voiders; routine use in CIC-dependent patients is not the AUA recommendation.[2]

Surgical​

  • Augmentation cystoplasty. AUA/SUFU states that clinicians may offer it to selected NLUTD patients with detrusor overactivity or poor compliance refractory to or intolerant of less invasive treatment . Ileum is typical; ileocecal bowel is used in selected cases. Assess patient or caregiver ability to perform CIC and counsel about stones, perforation, bowel dysfunction, mucus production and lifelong follow-up. After bowel reconstruction, obtain an annual focused history, physical examination, symptom assessment, basic metabolic panel and urinary tract imaging .[2]
  • Mitrofanoff or Monti catheterizable channel can facilitate CIC when wheelchair access, body habitus or prior urethral reconstruction makes urethral catheterization difficult, provided the patient or caregiver can catheterize the stoma reliably.[2][5]
  • Bladder-neck closure and continent catheterizable channel. In selected patients with refractory stress incontinence, closure is irreversible and requires reliable CIC through an existing or planned channel. When outlet closure could worsen compliance, assess storage pressure and compliance by urodynamics before surgery to protect the upper tracts .[2]
  • Ileal conduit or continent diversion. Salvage when reconstruction has failed or is not feasible.
  • Sacral neuromodulation. Guidelines differ. AUA/SUFU 2021 says not to offer SNM to patients with SCI or spina bifida.[2] EAU 2026 strongly recommends considering SNM in selected neurological patients and notes that MRI-compatible devices no longer require avoiding SNM in patients who need MRI follow-up; disease-specific evidence remains sparse, and patients with MS and NDO have often been reported as good responders to several types of neuromodulation.[5] In SCI, treat SNM as an exception requiring explicit counseling.[2][5]
  • Sacral anterior root stimulation (Brindley) with posterior rhizotomy. For selected patients with complete suprasacral lesions in investigational settings or specialty centers familiar with the operation and device (AUA/SUFU 2021); stimulation is above the pain threshold and post-stimulus voiding results from faster sphincter relaxation.[2][5] Rhizotomy abolishes reflex DO but also reflexes, sensation and erections, so it is now used mainly as an adjunct to SARS.[5] In an uncontrolled retrospective series of 104 patients (95 men, 9 women) undergoing extradural implantation and rhizotomy, urinary incontinence was reported in 100% before surgery versus 14% afterward, and urinary infection in 95/104 (91%) before versus 16/104 (15%) afterward.[19] Patient selection is restricted to a stable, complete spinal cord injury with intact sacral efferent pathways and a detrusor that contracts on stimulation; sacral anterior-root stimulation can also support defecation and erections through the same stimulated roots.[20] The rhizotomy is irreversible and sacrifices sacral sensation and reflexes, which is why it is reserved for complete lesions; incomplete deafferentation of an incomplete lesion has been described as a source of pain rather than relief.[21]
  • External sphincterotomy. Largely replaced by CIC plus medical therapy, but still effective in men who can wear a condom catheter for DSD, hydronephrosis, AD or recurrent UTI. It is irreversible, is best done at 12 o'clock with cold knife or laser, and often needs repeating.[5]

SCI-specific perioperative caveats​

  • Autonomic dysreflexia. For SCI at or above T6, assess AD risk before cystoscopy, urodynamics, and surgery, and monitor BP during instrumentation. Have a rapid-onset, short-acting antihypertensive (such as nitroglycerin paste or nifedipine) available. Urethral lidocaine can be considered before cystoscopy but may alter diagnostic urodynamics; do not give prophylactic antihypertensives before urodynamics. If AD develops during testing, AUA/SUFU 2021 requires immediate study termination, bladder drainage and continued BP monitoring; the SCI Consortium permits bladder drainage and treatment first, with procedure termination if AD remains uncontrolled. Check recent PDE5 inhibitor use before giving a nitrate. See Autonomic Dysreflexia.[1][27]
  • Positioning and pressure injury. Lithotomy or prone positioning with insensate skin; meticulous padding, frequent repositioning, and postop skin checks.
  • Spasticity. Baclofen pumps and botulinum-for-limb-spasticity regimens may interact with bladder care timing.
  • Heterotopic ossification. At hips; affects access and positioning.

Specific Scenarios​

Indwelling catheter exit — transitioning to CIC​

Assess whether CIC is feasible with the patient's dexterity, transfers, caregiver support, and goals. If a chronic indwelling catheter is required, AUA/SUFU favors suprapubic over urethral drainage to limit urethral injury. Neither approach removes infection or stone risk.[2]

UTI prevention​

  • Do not routinely screen for or treat asymptomatic bacteriuria in NLUTD .[1][5] Treatment exceptions are pregnancy and urologic procedures with anticipated urothelial disruption or upper-tract manipulation. New incontinence, spasticity, malaise, fever or AD can signal UTI in SCI; when infection is suspected, obtain urinalysis and urine culture .[1] Optimize emptying and remove stones and other foreign bodies.[1][5] Among patients using intermittent catheterization, hydrophilic catheters have been associated with fewer UTIs.[1][5]
  • Cranberry and probiotics have not shown benefit in RCTs, and methenamine hippurate is not effective in neurological patients (EAU 2026).
  • For select SCI patients on CIC with recurrent UTI, EAU 2026 offers weekly cycling of antibiotic prophylaxis; avoid continuous long-term antibiotics because of resistance.[5]

Bladder cancer surveillance​

  • Long-term indwelling catheterization is associated with bladder cancer, with SCC overrepresented. A meta-analysis found an incidence of about 6 per 1,000 SCI patients, squamous histology in roughly 37%, and diagnosis a mean of 24 years after injury.[9] A systematic review of 15 neuro-urological studies identified 332 bladder cancers (0.3% of patients); 98.8% of cancer cases had SCI.[16] Transitional cell carcinoma was the most frequent histology (53.1%), and cancer was diagnosed a mean of 24.9 years after onset of neurologic disease.[16]
  • AUA/SUFU recommends against routine screening or surveillance cystoscopy, including in chronic indwelling-catheter users (statements 19 and 20, strong recommendations, Grade B).[1]
  • Any gross hematuria, persistent irritative symptoms, or pelvic pain warrants cystoscopy and clinical evaluation rather than waiting for a scheduled visit.

Fertility and sexual health​

  • Erection physiology by injury level. Reflexogenic erection requires an intact sacral reflex arc (S2-S4) and pudendal nerve; psychogenic erection requires cortical input reaching an intact sympathetic erection center (T11-L2). A complete lesion above T10 usually preserves reflexogenic erections through the intact sacral arc while interrupting descending input to the T11–L2 psychogenic center. A sacral lesion that disrupts the S2–S4 reflex pathway may leave psychogenic arousal through T11–L2, often with limited rigidity. An injury between L2 and S2 gives a mixed, individually variable picture, sometimes retaining both mechanisms; a psychogenic erection in this setting tends to be engorged rather than rigid and short-lived, and is harder to treat. Acutely, spinal shock (flaccid paralysis and depressed reflexes, hours to weeks, occasionally with vasodilation-driven tumescence in a complete injury) precedes the return of spasticity and reflexes and then the chronic pattern set by level and completeness.[12][13]
  • Erectile dysfunction treatment. The EAU strongly recommends PDE5 inhibitors as first-line medical treatment for neurogenic ED; in pooled randomized crossover trials of men with SCI, successful intercourse attempts overall were 53% with sildenafil versus 12% with placebo, and benefit was also observed in men with complete SCI.[5][10] Intracavernosal injection or penile prosthesis may be considered when less invasive treatment fails.[5][10] Many SCI patients keep nitrates for autonomic dysreflexia, and PDE5 inhibitors are contraindicated with nitrates, so agree an alternative rescue agent first (see Autonomic Dysreflexia).[5][10]
  • Ejaculatory dysfunction. Penile vibratory stimulation (PVS) is the first sperm-retrieval step for SCI anejaculation; use electroejaculation (EEJ) if PVS fails, then consider testicular sperm extraction if both fail. For SCI at or above T6, counsel the patient and fertility team about AD, monitor BP during PVS or EEJ, and have rescue treatment available.[5][27] Retrieved sperm can be used with IUI, IVF, or ICSI.[5][28] Clean IC may preserve semen quality better than indwelling catheters or reflex voiding.[5] After a dry climax, sperm in post-ejaculatory urine supports retrograde ejaculation but is not conclusive because retained urethral semen can also make the sample positive; neurologic and surgical history helps distinguish retrograde ejaculation from failure of emission.[22][29] Absence of sperm alone does not establish failure of emission.[18][22]
  • Female SCI. Menstruation can stop for approximately six months after injury, while reproductive capacity appears to be temporarily affected. Pregnancy requires a bladder-management plan and coordinated obstetric delivery planning, including AD precautions for injuries at or above T6.[5][27]

Aging SCI population​

  • BPH. Increasingly common; treating in CIC patients requires balancing outlet resistance (needed for dry intervals between CIC) versus ease of catheter passage.
  • Prostate cancer. Screening with PSA in SCI follows general guidelines; transrectal biopsy requires AD prophylaxis.
  • Falls, cognitive decline, caregiver changes. Trigger reassessment of feasible bladder management.

Clinical Correlations for the Reconstructive Urologist​

  • Begin safe drainage and arrange reassessment early. Time video-urodynamics to clinical stability and risk; do not use a fixed post-injury waiting period to defer investigation of deterioration.[1]
  • Treat unsafe storage pressure and poor compliance in SCI. Escalate according to urodynamic findings and confirm the pressure response before relying on symptomatic improvement, particularly with β3 agonists; act before upper-tract changes or eGFR decline.[2][5]
  • Care is multidisciplinary. SCI medicine physiatrist, urologist, neuro-urology nurse / educator, physical therapy, and social work are the standard team.
  • Transition from pediatric SCI or spina bifida. Aging-out patients need deliberate handoff to adult reconstructive urology; otherwise they fall out of surveillance and present years later with advanced disease.

See Also​

Videos​

Management of Neurogenic Bladder After Spinal Cord Injury
Neurogenic Bladder Research Group (2021)

References​

1. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Diagnosis and Evaluation." J Urol. 2021;206(5):1097–1105. doi:10.1097/JU.0000000000002235

2. Ginsberg DA, Boone TB, Cameron AP, et al. "The AUA/SUFU Guideline on Adult NLUTD: Treatment and Follow-Up." J Urol. 2021;206(5):1106–1113. doi:10.1097/JU.0000000000002239

3. Milligan J, Goetz LL, Kennelly MJ. "A Primary Care Provider's Guide to Management of NLUTD and UTI After Spinal Cord Injury." Top Spinal Cord Inj Rehabil. 2020;26(2):108–115. doi:10.46292/sci2602-108

4. Romo PGB, Smith CP, Cox A, et al. "Non-Surgical Urologic Management of Neurogenic Bladder After Spinal Cord Injury." World J Urol. 2018;36(10):1555–1568. doi:10.1007/s00345-018-2419-z

5. European Association of Urology. Neuro-urology guideline, assisted bladder emptying. 2026. Accessed September 11, 2026.

6. Ginsberg D, Gousse A, Keppenne V, et al. "Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity." J Urol. 2012;187(6):2131-9. doi:10.1016/j.juro.2012.01.125

7. Bywater M, Tornic J, Mehnert U, et al. "Detrusor Acontractility after Acute Spinal Cord Injury-Myth or Reality?" J Urol. 2018;199(6):1565-1570. doi:10.1016/j.juro.2018.01.046

8. Agrawal M, Joshi M. "Urodynamic patterns after traumatic spinal cord injury." J Spinal Cord Med. 2015;38(2):128-33. doi:10.1179/2045772313Y.0000000136

9. Gui-Zhong L, Li-Bo M. "Bladder cancer in individuals with spinal cord injuries: a meta-analysis." Spinal Cord. 2017;55(4):341-345. doi:10.1038/sc.2016.151

10. Ohl DA, Carlsson M, Stecher VJ, et al. "Efficacy and Safety of Sildenafil in Men With Sexual Dysfunction and Spinal Cord Injury." Sex Med Rev. 2017;5(4):521-528. doi:10.1016/j.sxmr.2017.01.007

11. Lim V, Mac-Thiong JM, Dionne A, et al. "Clinical Protocol for Identifying and Managing Bladder Dysfunction during Acute Care after Traumatic Spinal Cord Injury." J Neurotrauma. 2021;38(6):718-724. doi:10.1089/neu.2020.7190

12. Krassioukov A, Elliott S. "Neural Control and Physiology of Sexual Function: Effect of Spinal Cord Injury." Top Spinal Cord Inj Rehabil. 2017;23(1):1-10. doi:10.1310/sci2301-1

13. Dimitriadis F, Karakitsios K, Tsounapi P, et al. "Erectile function and male reproduction in men with spinal cord injury: a review." Andrologia. 2010;42(3):139-165. doi:10.1111/j.1439-0272.2009.00969.x

14. Weld KJ, Wall BM, Mangold TA, Steere EL, Dmochowski RR. "Influences on renal function in chronic spinal cord injured patients." J Urol. 2000;164(5):1490-1493. doi:10.1016/s0022-5347(05)67013-9. PMID 11025689

15. Shamout S, Nazha S, Dragomir A, et al. "A cost-effectiveness analysis of bladder management strategies in neurogenic lower urinary tract dysfunction after spinal cord injury: A publicly funded health care perspective." Spinal Cord. 2023;61(4):269-275. doi:10.1038/s41393-023-00883-5

16. Ismail S, Karsenty G, Chartier-Kastler E, et al. "Prevalence, management, and prognosis of bladder cancer in patients with neurogenic bladder: A systematic review." Neurourol Urodyn. 2018;37(4):1386-1395. doi:10.1002/nau.23457

17. Gao Y, Danforth T, Ginsberg DA. "Urologic Management and Complications in Spinal Cord Injury Patients: A 40- to 50-year Follow-up Study." Urology. 2017;104:52-58. doi:10.1016/j.urology.2017.03.006

18. Milenković U, Albersen M. Erectile Dysfunction and Anejaculation in the Neurologic Patient. In: Dmochowski R, Heesakkers J, eds. Neuro-Urology. 1st ed. Springer; 2018:313-333. doi:10.1007/978-3-319-90997-4_19

19. Castaño-Botero JC, Ospina-Galeano IA, Gómez-Illanes R, Lopera-Toro A. "Extradural implantation of sacral anterior root stimulator in spinal cord injury patients." Neurourol Urodyn. 2016;35(8):970-974. doi:10.1002/nau.22838

20. Martens FM, Heesakkers JP. "Clinical results of a Brindley procedure: sacral anterior root stimulation in combination with a rhizotomy of the dorsal roots." Adv Urol. 2011;2011:709708. doi:10.1155/2011/709708

21. Martens FMJ, Heesakkers J. Sacral Dorsal Rhizotomy and Sacral Anterior Root Stimulation in Neurogenic Patients: The Brindley Procedure. In: Dmochowski R, Heesakkers J, eds. Neuro-Urology. 1st ed. Springer; 2018:421-433. doi:10.1007/978-3-319-90997-4_24

22. Shindel AW, Althof SE, Carrier S, et al. Disorders of Ejaculation: An AUA/SMSNA Guideline. J Urol. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392 (2020 guideline, Statement 19 discussion).

23. Cameron AP, Wallner LP, Tate DG, Sarma AV, Rodriguez GM, Clemens JQ. "Bladder management after spinal cord injury in the United States 1972 to 2005." J Urol. 2010;184(1):213-217. doi:10.1016/j.juro.2010.03.008

24. Myers J, Lenherr S, Stoffel J, Elliott S, Welk B, Presson A. "Comparing Bladder Management Strategies for People with Spinal Cord Injuries." Patient-Centered Outcomes Research Institute (PCORI) Final Research Report; 2020. doi:10.25302/06.2020.CER.140921348

25. Zadra A, Bruni S, De Tanti A, et al. "Life expectancy and long-term survival after traumatic spinal cord injury: a systematic review." Eur J Phys Rehabil Med. 2024;60(5):822-831. doi:10.23736/S1973-9087.24.08462-4

26. Kristensen T, Oturai PS, Haddock BT, Biering-Sørensen F, Kruuse C, Andersen UB. "Feasibility of replacing 99mTc-DTPA GFR measurements with eGFR from cystatin C in individuals with spinal cord injuries." Physiol Rep. 2025;13(9):e70315. doi:10.14814/phy2.70315

27. Krassioukov A, Linsenmeyer TA, Beck LA, et al. "Evaluation and Management of Autonomic Dysreflexia and Other Autonomic Dysfunctions: Preventing the Highs and Lows." J Spinal Cord Med. 2021;44(4):631-683. doi:10.1080/10790268.2021.1925058

28. Fode M, Ohl DA, Sønksen J. "A step-wise approach to sperm retrieval in men with neurogenic anejaculation." Nat Rev Urol. 2015;12:607–616. doi:10.1038/nrurol.2015.241

29. Veiga Álvarez E, Zopeque García N, Gutiérrez Romero JM, et al. "Sperm recovery from urine in men with retrograde ejaculation." Adv Lab Med. 2024;5(4):356-365. doi:10.1515/almed-2024-0109